Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

811.92 +4.25 (+0.53%)
Delayed Quote Updated: 3:35 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
66 67 Next >
News headline image
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗
The FDA is due to make an approval decision in mid-September for a key product from the top pharma company. 
Via Investor's Business Daily
News headline image
Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗
Via The Motley Fool
News headline image
What's going on in today's session: S&P500 movers ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
News headline image
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade ↗
Via The Motley Fool
News headline image
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls ↗
Unity diabetes study showing durable vision gains with full 36-week data expected in Q2 2025. 
Via Benzinga
News headline image
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty ↗
Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces potential investor obligations. 
Via Benzinga
News headline image
3 Reasons to Sell REGN and 1 Stock to Buy Instead
What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move. 
Via StockStory
News headline image
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Price Over Earnings Overview: Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
News headline image
Friday's session: top gainers and losers in the S&P500 index ↗
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
These S&P500 stocks are gapping in today's session ↗
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
News headline image
3 Stocks With Ironclad Balance Sheets for Long-Term Stability
Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market. 
Via MarketBeat
Topics Economy Supply Chain
News headline image
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
$250,000 top award goes to Matteo Paz in America’s longest running and most distinguished science and math competition 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Which S&P500 stocks are moving on Monday? ↗
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
REGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Top S&P500 movers in Monday's session ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study ↗
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies. 
Via Benzinga
News headline image
REGN Deadline: Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Deadline Soon: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients ↗
Eli Lilly's Ebglyss showed sustained eczema relief, with 50% achieving full skin clearance and 87% maintaining near-clear skin over three years. 
Via Benzinga
News headline image
Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
REGN DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Biotech Rally Coming In Weeks Ahead? ↗
Large cap biopharma and MedTech stocks are leading the healthcare sector higher. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial ↗
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent. 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.